Pacira BioSciences (NASDAQ:PCRX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Pacira BioSciences (NASDAQ:PCRX - Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $57.00 price target on the stock.

Other equities analysts have also issued research reports about the company. Needham & Company LLC lowered their price objective on Pacira BioSciences from $45.00 to $43.00 and set a buy rating on the stock in a research note on Wednesday. TheStreet upgraded shares of Pacira BioSciences from a d+ rating to a c rating in a research report on Thursday, February 29th. Wedbush reaffirmed an outperform rating and set a $57.00 target price on shares of Pacira BioSciences in a research note on Thursday, February 8th. Royal Bank of Canada dropped their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an outperform rating for the company in a research note on Friday, March 1st. Finally, JPMorgan Chase & Co. began coverage on shares of Pacira BioSciences in a research report on Thursday, March 7th. They set an overweight rating and a $45.00 price target on the stock. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $47.40.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX traded up $3.14 during midday trading on Wednesday, hitting $29.65. The company's stock had a trading volume of 1,961,053 shares, compared to its average volume of 507,365. The company has a market cap of $1.38 billion, a P/E ratio of 36.60 and a beta of 0.77. Pacira BioSciences has a 12-month low of $25.33 and a 12-month high of $43.50. The business's 50 day simple moving average is $28.27 and its 200 day simple moving average is $29.51. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, hitting analysts' consensus estimates of $0.71. The business had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. On average, analysts forecast that Pacira BioSciences will post 2.17 EPS for the current year.

Insider Transactions at Pacira BioSciences

In other news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the sale, the director now owns 22,127 shares of the company's stock, valued at $677,086.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Gary W. Pace sold 1,066 shares of the business's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now directly owns 140,384 shares of the company's stock, valued at $4,165,193.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gary W. Pace sold 90,000 shares of the company's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the sale, the director now owns 22,127 shares in the company, valued at $677,086.20. The disclosure for this sale can be found here. Company insiders own 6.60% of the company's stock.

Institutional Investors Weigh In On Pacira BioSciences

Large investors have recently modified their holdings of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Pacira BioSciences by 9.4% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company's stock worth $157,000 after purchasing an additional 438 shares in the last quarter. Texas Permanent School Fund Corp boosted its position in shares of Pacira BioSciences by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 40,642 shares of the company's stock worth $1,188,000 after acquiring an additional 543 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Pacira BioSciences by 96.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company's stock worth $36,000 after acquiring an additional 583 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC increased its holdings in shares of Pacira BioSciences by 5.6% in the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 11,185 shares of the company's stock valued at $343,000 after acquiring an additional 590 shares during the last quarter. Finally, Illinois Municipal Retirement Fund raised its position in shares of Pacira BioSciences by 2.2% during the 4th quarter. Illinois Municipal Retirement Fund now owns 26,964 shares of the company's stock worth $910,000 after acquiring an additional 591 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.